Recursion Pharmaceuticals
RXRX
133 hedge funds and large institutions have $861M invested in Recursion Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 45 increasing their positions, 33 reducing their positions, and 21 closing their positions.
38% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 21
36% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 33
33% more funds holding in top 10
Funds holding in top 10: 6 → 8 (+2)
27% more capital invested
Capital invested by funds: $680M → $861M (+$181M)
6.23% more ownership
Funds ownership: 58.75% → 64.98% (+6.2%)
4% more funds holding
Funds holding: 128 → 133 (+5)
15% less call options, than puts
Call options by funds: $499K | Put options by funds: $588K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCMU
MIC Capital Management (UK)
London,
United Kingdom
|
+$47.3M |
| 2 |
Norges Bank
Oslo,
Norway
|
+$19.1M |
| 3 |
BlackRock
New York
|
+$10.3M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$4.62M |
| 5 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$2.68M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$4.03M |
| 2 |
CC
Casdin Capital
New York
|
-$3.92M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$3.61M |
| 4 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$2.52M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
-$2.16M |
RXRX Hedge Fund Activity: Q2 2022 in Review
133 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Recursion Pharmaceuticals (RXRX) for Q2 2022, worth a combined $861M — up 27% from $680M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new RXRX positions and 21 closed out — a net gain of 8 holders — while 45 added to existing stakes and 33 trimmed.
The largest buyer was MIC Capital Management (UK), adding an estimated $47.3M. The largest seller was Citadel Advisors, cutting an estimated $4.03M.
- 133 institutional investors held Recursion Pharmaceuticals (RXRX) as of Q2 2022, up from 128 in Q1 2022.
- Funds reported $861M of Recursion Pharmaceuticals stock for Q2 2022, up 27% quarter-over-quarter.
- 29 funds opened new Recursion Pharmaceuticals positions in Q2 2022 and 21 closed out, a net change of +8 holders.
- The largest Recursion Pharmaceuticals buyer in Q2 2022 was MIC Capital Management (UK), an estimated $47.3M added.
- The largest Recursion Pharmaceuticals seller in Q2 2022 was Citadel Advisors, an estimated $4.03M sold.
Based on aggregated 13F filings for Q2 2022.